Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma - Wikidata - awgldk - TriplyDB

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

http://www.wikidata.org/entity/Q33385556

about

Pheochromocytoma: implications in tumorigenesis and the actual management Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model.Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.Neoplasms associated with germline and somatic NF1 gene mutations SDH-related pheochromocytoma and paraganglioma.Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment Metastatic paraganglioma.Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma Thyroid dysfunction from antineoplastic agents.Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG.False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy: A Case Report.Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.Sequelae and survivorship in patients treated with (131)I-MIBG therapy Combination chemotherapy regimen in a patient with metastatic malignant pheochromocytoma and neurofibromatosis type 1.Changing paradigms in the treatment of malignant pheochromocytoma.¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Radionuclide therapy of adrenal tumors.Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.Diagnosis and management of pheochromocytoma: a practical guide to clinicians.Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.Long clinical benefit achieved in two patients with malignant paraganglioma treated by metronomic cyclophosphamide.Management of Adrenal Masses.Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.An unusual case of gastrointestinal bleeding.Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.Peptide receptor radionuclide therapy for metastatic paragangliomas.Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience.[Malignant paraganglioma of the orbit, a case report].Patient with inoperable pheochromocytoma.Systemic therapies for malignant pheochromocytoma and paraganglioma can exacerbate hypertension.Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior.Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model.Norepinephrine Transporter as a Target for Imaging and Therapy.

P2860

Q27024128-813D726E-B403-409E-85D4-EB693D7E0D88 Q27027271-1B4381BC-FD7A-4428-B2F0-9A4FFF853F12 Q34038994-C8E49AFD-F1AE-43A4-9534-481CCD956A9F Q34117552-273DDECE-BD75-459B-9E6F-68BF46E0B564 Q34125947-69EC0F12-5915-4824-A53F-93731A9F46B3 Q34125978-E733CA20-49EE-4464-B29D-1A8495BDD648 Q34410500-73350884-850F-4BAD-A4D5-D0A1FFD1A321 Q34480015-8A88EB11-C3DE-458E-BFC8-4FA4A4CF794F Q35083673-4330B018-8E71-47B1-9AA1-FB41B661A413 Q35500038-7ED85FAB-7996-4510-8D40-B05A3690B2F2 Q35750737-F25462AA-DA5A-40E7-866B-BCD567B3567D Q36167038-9529ED31-C4BB-4A3C-9BCC-8A937AFB518D Q36195586-5022A3F6-73DD-4566-B5F6-2FD52675CB1D Q36625228-26D48B7D-0350-4397-8F06-7628023266BB Q36804496-0A721016-BC82-49CE-9828-EBDB8BB2B74D Q36932510-BA6DE7A9-C259-4D40-B04C-5F557C0F25ED Q37081870-ADADC453-AAD9-40CC-9DB8-81613F87B9AC Q37685580-17A555C3-B159-48C4-BA64-997998CC1EB0 Q37859612-947D2D7F-4CBF-4516-8DAC-CCFAA7848F25 Q37990403-4C2A0B7E-7601-4731-9D18-78EC267E5ADA Q38020428-06BA094B-4E4C-425D-88E2-CB53CB6620DE Q38106904-6301BD32-27D4-4686-A3E1-83D28927D88A Q38208963-36F1B3F3-C289-47A5-92AA-83DCE99F1A2B Q38849534-19880C05-95C1-48C6-86A4-5CB827BAF680 Q39084619-F84ACC75-F582-4DF7-8EF5-0FB42BEEA72B Q39105776-4BA14AA6-5EB7-43AF-A7E7-BFB7FE21A0C7 Q39152232-79114865-960E-4F08-84DE-CFECA14D1439 Q40327489-4CB59327-9832-4C93-B21A-639C9B1545F0 Q40339465-34132D70-0BCC-40FA-B032-8C09661C9565 Q40347934-5BB26FB1-1309-4560-A878-1EF812E435D5 Q40777229-DE0095F1-15D1-4E1E-87FC-1F553B41ACC6 Q40810595-DF8F1F06-A9B7-4C5C-8980-F6BB322EDF1A Q41161125-A0FB91BA-AF5F-426C-B2F7-15D8C53ACC7A Q41225447-D7009737-4AC1-479B-96F4-F09E35B08FC5 Q42268029-037FFCAD-D82B-4A84-9423-EA059F3FC405 Q42534100-216E69BE-1523-4EAA-84E0-9106A43A73E4 Q45900034-E0C2C1FB-BA90-4E38-89BF-D0C2C78420DC Q47181092-6E6C6E95-D999-45C7-A898-3BA800DD3ED8 Q47557128-7CA93B43-44A1-4CE1-B41D-811FA7C03748 Q47867820-5CB6411C-7C70-4DD4-962F-0CC4B88AD5E6

P2860

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

http://www.wikidata.org/entity/Q33385556

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@ast

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@en

type

label

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@ast

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@en

prefLabel

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@ast

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@en

P1433

Q33385556-7269258F-F6EE-4D15-A25D-805928FF6FF7

P1476

Q33385556-ECAFE005-4DA7-4D87-BDD6-D19D7C49BE98

P2093

Q33385556-161A7AD6-C960-4B4C-AE68-71B3019BF7B3

Q33385556-2F7A8AFA-3D98-4C7A-AE9C-03216FD68919

Q33385556-306B790C-C68C-49DE-BB60-41D11187B5E5

Q33385556-324E48D0-C577-4C6D-8F7E-BF010C9ED8B7

Q33385556-5792CC3D-02C3-4CCB-8FCF-91CE632BDC32

Q33385556-5FA0DD8C-5CF6-4FB0-9231-9E3CBC6C5FBB

Q33385556-86F06D38-3455-43AC-B639-668EF5A90BE7

Q33385556-9172AA40-B4B2-482E-805B-64DB31F038FB

Q33385556-AA411AEE-5E54-44FF-A918-0D128F058A0C

Q33385556-C6DA5903-1928-432B-9590-B8FDD6E588A9

P2860

Q33385556-0758FDDE-396D-499A-8921-E862A652EBE4

Q33385556-09331506-28E4-40B2-ADCF-B5AB22F88CF4

Q33385556-0EE9C460-454B-44F7-81AE-A9A182D7EE84

Q33385556-15F8CC8A-F9A5-496D-9C61-CBD5DF1BA7F3

Q33385556-2631066C-ACAF-478B-B7F2-F4290528DB85

Q33385556-27DD956D-93AB-4334-B598-FD4B1EDA154A

Q33385556-302C172B-C335-4D67-8A16-5A96035E7AE0

Q33385556-4D7DC770-3DD6-4FBB-836E-2A48FBCF8602

Q33385556-61FB8815-D28F-4580-A0BD-CEC5DACF5006

Q33385556-647A17A2-EFF7-4481-AA32-DDF544FA16D6

P304

Q33385556-00F6612C-13DD-4E06-8980-7376B794CD65

P31

Q33385556-7A6ACD2D-3248-4899-828B-F084386C4D8F

P356

Q33385556-E6506BA0-AFCD-4D62-8864-81C505328C70

P407

Q33385556-DAD99E46-D769-4457-8409-C8C7D7F157BA

P433

Q33385556-03AB0756-0B1E-4519-895A-DAFFAA17866A

P478

Q33385556-2E7198A2-01F9-43C2-9E0B-E87D09BCB1A2

P577

Q33385556-E1111F12-4697-4543-BCD5-6AE180B8BEA0

P698

Q33385556-1942ED41-B66D-41D0-8931-D87829A67010

P921

Q33385556-F8C76FAD-F5F9-46E4-97DD-ABA4ECDDD100

P932

Q33385556-4F5017AB-E448-4C6B-B203-1A897E7B2074

P356

JCO.2008.21.3496

P1433

Journal of Clinical Oncology

P1476

Phase II study of high-dose [1 ...... chromocytoma and paraganglioma

@en

P2093

Aimee Sznewajs

http://www.w3.org/2001/XMLSchema#string

Charles Linker

http://www.w3.org/2001/XMLSchema#string

David Price

http://www.w3.org/2001/XMLSchema#string

John Huberty

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

Lloyd Damon

http://www.w3.org/2001/XMLSchema#string

Paul Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Randall Hawkins

http://www.w3.org/2001/XMLSchema#string

Robert Goldsby

http://www.w3.org/2001/XMLSchema#string

Sara Gonias

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.

Fatal form of phaeochromocytoma presenting as acute pyelonephritis.

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.

Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma

Pheochromocytoma: an update on genetics and management.

P304

4162-4168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.21.3496

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19636009

http://www.w3.org/2001/XMLSchema#string

P921

phaeochromocytoma

P932

2734428

http://www.w3.org/2001/XMLSchema#string